Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1

NCT02600429 is registered in ClinicalTrials.gov with ReGenTree, LLC as lead sponsor.

NCT NCT02600429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02600429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1
Lead sponsor
ReGenTree, LLC
Phase
Phase 3
Overall status
Terminated
Start date
September 17, 2015
Completion date
March 9, 2020
Enrollment
18 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neurotrophic keratopathy